Ben Sasse Underwent Liver Cancer Surgery
The former senator and university president modified his cancer treatment after discovering resistance to prior therapies.
Updated on Sept. 23, 2026 in Cancer
Ben Sasse, 54, underwent surgery to remove cancer from his liver at MD Anderson Cancer Center in Houston. Doctors initiated an aggressive chemotherapy protocol following tests that indicated his pancreatic cancer had developed resistance to previous treatment.
Why it matters
The change in clinical approach follows the failure of the initial treatment plan, which had been in place since Sasse began a clinical trial for the drug daraxonrasib in early 2026.
Sasse was initially diagnosed with Stage 4 pancreatic cancer in December 2025, which carried an estimated life expectancy of 3 to 4 months at that time. He is now 54 years old and has been undergoing intensive medical interventions.
The players
Ben Sasse
He is a former U.S. Senator for Nebraska who served from 2015 to 2023 and is a former president of the University of Florida.
MD Anderson Cancer Center
This is a comprehensive cancer center located in Houston that provides specialized oncological surgery and research.
Food and Drug Administration
This federal agency is responsible for protecting public health by regulating medical products and granting drug approvals.
The details
Surgeons in Houston successfully removed a significant amount of cancerous tissue from the liver last week. The medical team shifted the treatment strategy after mutation testing revealed the disease had advanced despite earlier efforts.
Timeline
Ben Sasse served as a U.S. Senator for Nebraska from 2015 to 2023.
He revealed his Stage 4 pancreatic cancer diagnosis in December 2025.
Sasse began a clinical trial for daraxonrasib in January 2026.
The FDA granted accelerated approval for daraxonrasib in late August 2026.
Sasse underwent liver surgery in September 2026.
The Big Picture
The clinical trial for daraxonrasib represents a frontier in targeted therapy for pancreatic cancer. This development highlights the ongoing struggle to overcome tumor mutation and treatment resistance in advanced-stage diagnoses.
Patients dealing with Stage 4 diagnoses must often navigate rapid changes to treatment plans as tumors develop resistance. This news underscores the importance of ongoing genetic testing and the necessity of monitoring for treatment failure throughout clinical trials.
The takeaway
Advanced pancreatic cancer remains a complex condition where the efficacy of novel therapies can shift quickly. Monitoring for treatment resistance is a critical component of long-term care management for patients in similar clinical trials.
What happens next
Ben Sasse is scheduled to serve as the keynote speaker at the Governor's Summit in Kearney, Nebraska, next week.
Further reading
For more information on current treatment landscape, visit Cancer.
